The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease

International Journal of Neuropsychopharmacology

Volumn 3, Issue SUPPL. 2, 2000, Pages

  Cummings, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Behaviour; Cholinesterase inhibitors; Treatment

Indexed keywords

CHOLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; METRIFONATE; NERVE GROWTH FACTOR; PHOSPHATIDYLCHOLINE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL;

EID: 0033920019     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1461145700001917     Document Type: Conference Paper

References (63)

1. Blurton-Jones MM, Roberts JA, Tuszynski MH (1999). Estrogen receptor immunoreactivity in the adult primate brain: neuronal distribution and association with p75, trkA, and choline acetyltransferase. Journal of Comparative Neurology 405 (4), 529-542.
2. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM (1997). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Archives of Neurology 54, 465-473.
3. Bums A, Rossor M, Hecker J, Gauthier S, Petit H, Möller H-J, Rogers SL, Friedhoff LT and the International Donepezil Study Group (1999). The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dementia and Geriatric Cognitive Disorders 10 (3), 237-244.
4. Cooper JR, Bloom FE, Roth RH (1996). The Biochemical Basis of Neuropharmacology (7th edn). New York: Oxford University Press.
5. Coyle JT, Price DL, DeLong MR (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219, 1184-1190.
6. Craig AH, Cummings JL, Fairbanks L, Itti L, Miller BL, Li J, Mena I (1996). Cerebral blood flow correlates of apathy in Alzheimer's disease. Archives of Neurology 53, 1116-1120.
7. Cummings JL, Back C (1998). The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. American Journal of Geriatric Psychiatry 6 (2 Suppl. 1), S64-S78.
8. Cummings JL, Benson DF (1987). The role of the nucleus basalis of Meynert in dementia: review and reconsideration. Alzheimer Disease and Associated Disorders 1, 128-145.
9. Cummings JL, Benson DF (1992). Dementia: a Clinical Approach (2nd edn). Boston: Butterworth-Heinemann.
10. Cummings JL, Cyrus P, Bieber F, Orazem J, Mas J, Gulanski B (1998). The effect of metrifonate on the cognitive, functional, and behavioral symptoms of Alzheimer's disease. Abstract presented at the American Association for Geriatric Psychiatry, San Diego, California, USA.
11. Cummings JL, German DG, Shapira J (1993). Physostigmine ameliorates the delusions of Alzheimer's disease. Biological Psychiatry 33, 536-541.
12. Cummings JL, Kaufer D (1996). Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 47, 876-883.
13. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gombein J (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
14. Cummings JL, Victoroff JI (1990). Noncognitive neuropsychiatric syndromes in Alzheimer's disease. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 3, 140-158.
15. Davies P (1978). Studies on the neurochemistry of central cholinergic systems in Alzheimer's disease. In: Katzman R, Terry RD, Bick KL (Eds.), Alzheimer's Disease: Senile Dementia and Related Disorders (pp. 453-459). New York: Raven Press.
16. Devanand DP, Miller L, Richards M, Marder K, Bell K, Mayeux R, Stem Y (1992). The Columbia University Scale for Psychopathology in Alzheimer's disease. Archives of Neurology 49 (4), 371-376.
17. Drachman DA (1977). Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 27, 783-790.
18. Dubois B, Pillon B, Lhermitte F, Agid Y (1990). Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Annals of Neurology 28, 117-121.
19. Eisdorfer C, Cohen D, Paveza GJ, Ashford JW, Luchins DJ, Gorelick PB, Hirschman RS, Freels SA, Levy PS, Semla TP, Shaw HA (1992). An empirical evaluation of the Global Deterioration Scale for staging Alzheimer's disease. American Journal of Psychiatry 149 (2), 190-194.
20. Fowler CJ, Garlind A, O'Neill C, Cowburn RF (1996). Receptor-effector coupling dysfunctions in Alzheimer's disease. Annals of the New York Academy of Sciences 786, 294-304.
21. Geula C, Mesulam M-M (1994). Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. In: Terry RD, Katzman R, Bick KL (Eds.), Alzheimer's Disease (pp. 263-291). New York: Raven Press.
22. Gibbs RB, Aggarwal P (1998). Estrogen and basal forebrain cholinergic neurons: implications for brain aging and Alzheimer's disease-related cognitive decline. Hormones and Behaviour 34 (2), 98-111.
23. Gorman DG, Read S, Cummings JL (1993). Cholinergic therapy of behavioral disturbances in Alzheimer's disease. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 6, 229-234.
24. Green CR, Marin DB, Mohs RC, Schmeidler J, Aryan M, Fine E, Davis KL (1999). The impact of behavioral impairment of functional ability in Alzheimer's disease. International Journal of Geriatric Psychiatry 14, 307-316.
25. Hutchinson M, Fazzini E (1996). Cholinesterase inhibition in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 61, 324-325.
26. Janowsky DS, Risch SC, Gillin JC (1983). Adrenergic-cholinergic balance and the treatment of affective disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 7, 297-307.
27. Kaufer DI (1999). Core neuropsychiatric symptom response profile to cholinergic therapy in Alzheimer's disease: clinical and neurobehavioural relevance. Neurology 52 (6 Suppl. 2), A182 (S25.002).
28. Kaufer DI, Call K, Pollock BG, Lopez OM, DeKosky ST (1998b). Donepezil in Alzheimer's disease: relative cognitive and neuropsychiatric responses and impact on caregiver distress. Neurology 50 (4 Suppl. 4), A89 (P02.013).
29. Kaufer DI, Cummings JL, Christine D (1996). Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. Journal of Geriatric Psychiatry and Neurology 9, 1-6.
30. Kaufer DI, Cummings JL, Christine D (1998a). Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. Journal of Neuropsychiatry and Clinical Neurosciences 10, 55-63.
31. Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA, Kilbourn MR (1999). In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 52 (4), 691-699.
32. Kumar V, Calache M (1991). Treatment of Alzheimer's disease with cholinergic drugs. International Journal of Clinical Pharmacology and Therapeutics 29, 23-37.
33. Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta (1996). A longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. American Journal of Psychiatry 153 (11), 1438-1443.
34. Levy ML, Cummings JL, Kahn-Rose R (1999). Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology 45 (Suppl. 1), 15-22.
35. Lindesay J, Macdonald A, Starke I (1990). Delirium in the Elderly. Oxford: Oxford University Press.
36. Longo VG (1966). Behavioral and electroencephalagraphic effects of atropine and related compounds. Pharmacological Reviews 18, 965-996.
37. Mega M, Cummings JL, Fiorello T, Gombein J (1996). The spectrum of behavioral changes in Alzheimer's disease. Neurology 46, 130-135.
38. Mentis MJ, Weinstein EA, Horwitz B, McIntosh AR, Pietrini P, Alexander GE, Furey M, Murphy DG (1995). Abnormal brain glucose metabolism in the delsuional misidentification syndromes: a positron emission tomography study in Alzheimer's disease. Biological Psychiatry 38, 438-449.
39. Mesulam M-M, Mufson EJ (1984). Neural inputs into the nucleus basalis of the substantia innominata (Ch 4) in the rhesus monkey. Brain 107, 253-274.
40. Mesulam M-M, Mufson EJ, Levey AI, Wainer BH (1983). Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. Journal of Comparative Neurology 214, 170-197.
41. Molchan SE, Vitiello B, Minichiello M, Sunderland T (1991). Reciprocal changes in psychosis and mood after physostigmine in a patient with Alzheimer's disease [letter]. Archives of General Psychiatry 48, 1113.
42. Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B (1998). Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 50 (5), 1222-1230.
43. Nieuwenhuys R (1985). Chemoarchitecture of the Brain. New York: Springer-Verlag.
44. O'Donnell BF, Drachman DA, Barnes HJ, Peterson KE, Swearer JM, Lew RA (1992). Incontinence and troublesome behaviors predict institutionalization in dementia. Journal of Geriatric Psychiatry and Neurology 5, 45-52.
45. Perry EK, Kerwin J, Perry RH, Irving D, Blessed G, Fairbairn A (1990). Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of Lewy body type. Dementia 1, 2-4.
46. Pettenati C, Donato MF (1998). Behavioral symptoms of Alzheimer's disease: improvement by donepezil. Neurobiology of Aging 19 (4S), S182 (763).
47. Procter AW, Lowe SL, Palmer AM, Francis PT, Esiri MM, Stratmann GC, Najlerahim A, Patel AJ, Hunt A, Bowen DM (1988). Topographical distribution of neurochemical changes in Alzheimer's disease. Journal of Neurological Sciences 84, 125-140.
48. Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB (1997). Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer's disease. Archives of Neurology 54, 836-840.
49. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group (1998). A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50, 136-145.
50. Samuels SC, Davis KL (1997). A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease. Drug Safety 16, 66-77.
51. Schliebs R, Robner S (1995). Distribution of muscarinic acetylcholine receptors in the CNS. In: Stone TW (Ed.), CNS Neurotransmitters and Neuromodulators: Acetylcholine (pp. 67-83). Boca Raton, FL: CRC Press.
52. Smucker WD (1996). Maximizing function in Alzheimer's disease: what role for tacrine? American Family Physician 54 (2), 645-652.
53. Starkstein SE, Vazquez S, Petracca G, Sabe L, Migliorelli R, Teson A, Leiguarda R (1994). A SPECT study of delusions in Alzheimer's disease. Neurology 44 (11), 2055-2059 .
54. Sultzer DL, Mahler ME, Mandelkern MA, Cummings JL, Van Gorp WG, Hinkin CH, Berisford MA (1995). Psychiatric symptoms are associated with regional cortical metabolism in Alzheimer's disease. Journal of Neuropsychialry and Clinical Neurosciences 7, 476-484.
55. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller 3rd EA, Murphy DL (1987). Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. Archives of General Psychiatry 44, 418-426.
56. Sunderland T, Tariot PN, Newhouse PA (1988). Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Research Reviews 13, 371-389.
57. Treanor J, Beck K, Hefti F (1995). Neuronal growth factors and Alzheimer's disease. In: Dawbarn D, Allen SJ (Eds.), Neurobiology of Alzheimer's Disease (pp. 249-259). Bristol: Bios Scientific Press.
58. Troisi A, Pasini A, Gori G, Sorbi T, Biagini C, Aulisi A, Baroni A, Ciani N (1993). Assessment of depression in Alzheimer's disease: symptoms, syndrome, and computed tomography findings. Dementia 4 (2), 87-93.
59. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW (1994). Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. Journal of the American Medical Association 271, 992-998.
60. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR (1981). Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Annals of Neurology 10, 122-126.
61. Wilcock GK, Esiri MM, Bowen DM, Smith CC (1982). Alzheimer's disease. Correlation of cortical cholinergic acetyltransferase activity with the severity of dementia and histopathological abnormalities. Journal of Neurological Sciences 57, 407-417.
62. Winblad B, Messamore E, O'Neill C, Cowburn R (1993). Biochemical pathology and treatment strategies in Alzheimer's disease: emphasis on the cholinergic system. Acta Neurologica Scandinavica Supplementum 149, 4-6.
63. Wragg RE, Jeste DV (1989). Overview of depression and psychosis in Alzheimer's disease. American Journal of Psychiatry 146, 577-587.